Inositec AG

Swiss Biotech Association

Member

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. The company's current focus is on developing the cardiovascular calcification inhibitor INS-3001 as a first-in-class treatment for aortic valve stenosis. Inositec was founded in December 2015 as a spin-off of ETH Zurich.

Location

Technoparkstrasse 1, 8005 Zürich, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2015
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Limula SA

Limula SA is developing a platform technology to enable scale out of cell therapy manufacturing, directly at the point of care. We support companies at all stages of the life cycle of their therapies, from R&D to routine production.
La Tour-de-Peilz

Member

Laevoroc Oncology AG

Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies that leverages word-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
Hünenberg

Member

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil

Member